Crimson Publishers- Novel Approaches in Cancer Study

Molecular Detection of Epstein-Barr Virus and Human Cytomegalovirus Antigen Expression in Breast Cancer in Khartoum State, Sudan 2018 by Khalid A Enan in Journal of Cancer Research   Crimson Publishers_   Novel Approaches in Cancer Study Breast cancer is a leading cause of death among women worldwide. The association between Epstein-Barr Virus (EBV) and Human Cytomegalovirus (HCMV) and breast cancer risk still remains controversial making it difficult to determine whether either, both or neither virus is causally associated with breast cancer. The aim of this study was to detect EBV and the expression of the Immediate Early Antigen (IE) of HCMV in breast cancer in Sudanese women.  https://crimsonpublishers.com/nacs/fulltext/NACS.000560.ph please click on the link https://www.scilit.net/publisher/9410/10350

Different Faces of Fas Signaling in Cancer Cells by Magdalena Szarynska in Journal of Cancer Research   Crimson Publishers_   Novel Approaches in Cancer Study  Fas signaling pathway is known to be engaged in elimination of unwanted cells by apoptosis, however, new discoveries presented its alternate face, namely FasR and FasL play pro-cancerous functions facilitating cancer progression, invasion and metastasis. Here, we provide a brief summary of knowledge concerning Fas signaling pathway merits and disadvantages in cancer. Fas molecules were found to be engaged in many pathways induced by different therapeutic compounds, such as aspirin and antibiotics. This suggest that Fas signaling pathway may be employed as adjuvant factor for immunotherapy of variable design. Although, the literature presents some first optimistic results, we must intensify efforts to finally introduce Fasassociated procedures into standard therapeutic options. The Fas signaling is known to exert ve...

Identifying Biomarkers for Diffuse Large B-Cell Lymphoma Subtypes by Nita Parekh in Journal of Cancer Research   Crimson Publishers_   Novel Approaches in Cancer Study Diffuse Large B-cell Lymphoma (DLBCL) is a highly heterogeneous cancer of B cells. Apart from cell-of-origin, genetic variations have been observed to contribute towards heterogeneity leading to different pathogenic mechanisms and overall survival outcomes. Various classification schemes have been proposed that may aid in risk stratification and developing new therapeutics for those who fail frontline therapy. This mini review highlights the significance of genetic variations as biomarkers for DLBCL and ease in extending it to clinical setting. https://crimsonpublishers.com/nacs/fulltext/NACS.000558.php   please click on the link https://www.scilit.net/publisher/9410/10350